Aquinox Pharmaceuticals completes patient enrolment in Phase II KINSHIP trial of AQX-1125.
M2 PHARMA-May 6, 2015-Aquinox Pharmaceuticals completes patient enrolment in Phase II KINSHIP trial of AQX-1125
(C)2015 M2 COMMUNICATIONS
Canada-based Aquinox Pharmaceuticals has completed patient enrolment in the Phase II KINSHIP trial of its lead drug candidate, AQX-1125, it was reported on Tuesday.
The product is intended to treat atopic dermatitis and is a small molecule activator of SHIP1 suitable for oral, once daily dosing, which has been assessed in multiple preclinical studies and clinical trials.
The randomised, double-blind, multicentre, placebo-controlled KINSHIP trial is being conducted at sites in Canada to evaluate the efficacy and safety of AQX-1125 in around 50 adult patients with mild to moderate atopic dermatitis, as a proof-of-concept trial in this indication.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||May 6, 2015|
|Previous Article:||China Food and Drug Administration grants approval to Bayer's Xarelto.|
|Next Article:||Bactiguard signs agreement for distribution in Israel.|